ReviewCells2021
Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CRISPR-Based Gene Therapy for Brain Disease.Molecular neurobiology · 2026Review
- Cellular Allies Against Glioblastoma: Therapeutic Potential of Macrophages and Mesenchymal Stromal Cells.Pharmaceutics · 2026Review
- Combined Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary and Recurrent Glioblastoma (GBM).Cancers · 2025Review
- Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.Journal of neuro-oncology · 2025Review
- Stem cell therapies and glioma stem cells in glioblastoma: a systematic review of current challenges and research directions.International journal of emergency medicine · 2025Review
- Expression profile and prognostic relevance of immune infiltration-related RBMS1 in gliomas: a multidimensional integrative analysis.Journal of cancer research and clinical oncology · 2025Article
- Recent Advances in the Delivery of Bone Morphogenetic Proteins for Targeting Glioma: An Updated Review.International journal of nanomedicine · 2025Review
- OTUB1 Promotes Glioblastoma Growth by Inhibiting the JAK2/STAT1 Signaling Pathway.Journal of Cancer · 2024Article
- CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.Journal for immunotherapy of cancer · 2023Article
- Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.Molecules (Basel, Switzerland) · 2023Review
- Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing.International journal of molecular sciences · 2022Review
- Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.International journal of molecular sciences · 2022Review
- The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma.Frontiers in molecular biosciences · 2022Review
- Advanced Cell Therapies for Glioblastoma.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has become, over time, the impetus for the discipline of bringing novel therapeutics to the surface and challenging them so they can be improved. The cell-based approach in treating GB found its way to clinical trials thanks to a marvelous number of preclinical studies that probed various types of cells aiming to combat GB and increase the survival rate. In this review, we aimed to summarize and discuss the up-to-date preclinical studies that utilized stem cells or immune cells to treat GB. Likewise, we tried to summarize the most recent clinical trials using both cell categories to treat or prevent recurrence of GB in patients. As with any other therapeutics, cell-based therapy in GB is still hampered by many drawbacks. Therefore, we highlighted several novel techniques, such as the use of biomaterials, scaffolds, nanoparticles, or cells in the 3D context that may depict a promising future when combined with the cell-based approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.